Last10K.com

Marina Biotech, Inc. (MRNA) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

Adhera Therapeutics, Inc.

CIK: 737207
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2017
Nov. 13, 2017
Document And Entity Information  
Entity Registrant NameMarina Biotech, Inc. 
Entity Central Index Key0000737207 
Document Type10-Q 
Document Period End DateSep. 30, 2017 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Filer CategorySmaller Reporting Company 
Entity Common Stock, Shares Outstanding 10,521,278
Trading SymbolMRNA 
Document Fiscal Period FocusQ3 
Document Fiscal Year Focus2017 

View differences made from one quarter to another to evaluate Adhera Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adhera Therapeutics, Inc..

Continue

Assess how Adhera Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Adhera Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (parenthetical)
Condensed Consolidated Statements Of Cash Flows (unaudited)
Condensed Consolidated Statements Of Changes In Stockholders' Equity (unaudited)
Condensed Consolidated Statements Of Operations (unaudited)
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Intangible Assets
Intangible Assets (details Narrative)
Intangible Assets (tables)
Intangible Assets - Schedule Estimate Of Fair Value Of Assets Acquired And Liabilities (details)
Intangible Assets - Schedule Merger Agreement Based On Common Stock Outstanding (details)
Intangible Assets - Schedule Of Intangible Assets (details)
Intellectual Property And Collaborative Agreements
Intellectual Property And Collaborative Agreements (details Narrative)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies (details Narrative)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies (policies)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies (tables)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Anti-dilutive Securities (details)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Fair Value Liability Of Price Adjustable Warrants Determined By Level 3 (details)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Fair Value Of Derivative Liability Determined By Level 3 (details)
Nature Of Operations, Basis Of Presentation And Significant Accounting Policies - Schedule Of Liabilities Measured At Fair Value On Recurring Basis (details)
Notes Payable
Notes Payable (details Narrative)
Related Party Transactions
Related Party Transactions (details Narrative)
Stock Incentive Plans
Stock Incentive Plans (details Narrative)
Stock Incentive Plans (tables)
Stock Incentive Plans - Schedule Of Stock Option Activity (details)
Stock Incentive Plans - Schedule Of Summary Of Additional Information On Stock Options Outstanding (details)
Stockholders' Equity
Stockholders' Equity (details Narrative)
Stockholders' Equity (tables)
Stockholders' Equity - Schedule Of Warrant Activity (details)
Subsequent Events
Subsequent Events (details Narrative)
CIK: 737207
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-17-012923
Submitted to the SEC: Mon Nov 13 2017 4:59:51 PM EST
Accepted by the SEC: Mon Nov 13 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/737207/0001493152-17-012923.htm